Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02648490
Title An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Henlix, Inc
Indications

carcinoma

Advanced Solid Tumor

Therapies

Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron

HLX07

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST